CN104984408A - Medicine covered stent used for aorta endovascular graft exclusion - Google Patents
Medicine covered stent used for aorta endovascular graft exclusion Download PDFInfo
- Publication number
- CN104984408A CN104984408A CN201510388578.3A CN201510388578A CN104984408A CN 104984408 A CN104984408 A CN 104984408A CN 201510388578 A CN201510388578 A CN 201510388578A CN 104984408 A CN104984408 A CN 104984408A
- Authority
- CN
- China
- Prior art keywords
- medicine
- overlay film
- film frame
- aortic repair
- endovascular aortic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a medicine covered stent used for aorta endovascular graft exclusion. Medicine on the medicine covered stent is released slowly to restrain lesions and relieve inflammatory response, so that adverse events after the endovascular graft exclusion are reduced. The medicine covered stent used for the aorta endovascular graft exclusion comprises a nitinol alloy skeleton and an expanded polytetrafluoroethylene film on the surface of the nitinol alloy skeleton and is characterized in that the expanded polytetrafluoroethylene film is wrapped by a medicine membrane, and the thickness of the medicine membrane is 1-10 micrometers.
Description
Technical field
The present invention relates to a kind of medicine overlay film frame of Endovascular aortic repair.
Background technology
Along with raising and the population structure aging of living standards of the people, the incidence rate of vascular system disease and disable, fatality rate rises year by year, and dissection of aorta is a wherein the most dangerous class.In aorta lumen, extensively carrying out of less invasive techniques significantly reduces this type of death risk, improves disease prognosis.Although mostly the existing overlay film frame for Endovascular aortic repair is biocompatible materials, but the interaction between support and aorta tube wall often causes inflammation to react and causes abnormal vascular remodeling, it is the major reason of inner cavity insulation postoperative generation adverse events (as stent migration, against tearing new hair clip layer, internal hemorrhage due to trauma etc.).
Summary of the invention
For solving the problem, the invention provides a kind of medicine overlay film frame of Endovascular aortic repair, reduce inflammation reaction, thus reduce the generation of the postoperative adverse events of inner cavity insulation.
For achieving the above object, the present invention proposes following technical scheme:
A medicine overlay film frame for Endovascular aortic repair, comprises the eptfe membrane on nickel-titanium alloy framework and its surface, it is characterized in that:
Wherein, also wrap up one deck pharmaceutical film outward at eptfe membrane, pharmaceutical film thickness is 1 ~ 10 μm.
The medicine overlay film frame of Endovascular aortic repair provided by the invention, can also have following characteristics:
Wherein, nickel-titanium alloy framework is hollow cylindrical, and the length of nickel-titanium alloy framework is 105 ~ 215mm, and the internal diameter after strutting is 24 ~ 46mm.
The medicine overlay film frame of Endovascular aortic repair provided by the invention, can also have following characteristics:
Wherein, pharmaceutical film is made up of complex fiber material, the mixed solution that complex fiber material is made up of organic polymer and drug molecule, adopts electrostatic textile technology to make, and drug molecule is the combination of any one or 2 ~ 4 kinds in glucocorticoid, aspirin, rapamycin, paclitaxel.
The medicine overlay film frame of Endovascular aortic repair provided by the invention, can also have following characteristics:
Wherein, glucocorticoid is any one in prednisolone, betamethasone, dexamethasone, beclomethasone.
The medicine overlay film frame of Endovascular aortic repair provided by the invention, can also have following characteristics:
Wherein, described organic polymer is any one in polylactic acid, Poly(D,L-lactide-co-glycolide, polylactic-co-glycolic acid.
The medicine overlay film frame of Endovascular aortic repair provided by the invention, can also have following characteristics:
Wherein, described organic polymer molecular weight is 5 ~ 500,000.
Invention effect and effect
In the medicine overlay film frame implant into body of Endovascular aortic repair provided by the invention, not only can completely cut off breach, and the sustained release on medicine overlay film frame, reach and suppress pathological changes to occur, reduce inflammation reaction, thus reduce the object of the postoperative adverse events generation of inner cavity insulation.
Accompanying drawing explanation
Fig. 1 is the medicine overlay film frame structural representation of Endovascular aortic repair provided by the invention.
Detailed description of the invention
Below in conjunction with accompanying drawing, the specific embodiment of the present invention is described.
Fig. 1 is the medicine overlay film frame structural representation of the Endovascular aortic repair in the present embodiment.
As shown in Figure 1, the medicine overlay film frame 100 of Endovascular aortic repair in the present embodiment, comprise nickel-titanium alloy framework 1, its surface eptfe membrane 2 and be coated on the pharmaceutical film 3 of eptfe membrane 2 outer surface.The medicine overlay film frame 100 of Endovascular aortic repair adopts the support of different size according to the different patient's condition of different patient, support is hollow tubular, and length can be 105 ~ 215mm, struts rear inside diameter ranges and can be 24 ~ 46mm.
Pharmaceutical film is made up of complex fiber material, the mixed solution that complex fiber material is made up of organic polymer and drug molecule, adopts electrostatic textile technology to make.Pharmaceutical film thickness is 1 ~ 10 μm.Drug molecule is the combination of any one or 2 ~ 4 kinds in glucocorticoid, aspirin, rapamycin, paclitaxel.Organic polymer is any one in polylactic acid, Poly(D,L-lactide-co-glycolide, polylactic-co-glycolic acid.Glucocorticoid can be in prednisolone, betamethasone, dexamethasone, beclomethasone any one.
Medicine overlay film frame preparation method is as follows:
A) drug molecule is dissolved in solvent, ultrasonic 10 ~ 20 minutes, stirring at room temperature 2 ~ 4 hours;
B) be dissolved in by organic polymer in the solution of drug containing molecule in a, wherein organic macromolecule mass percentage concentration is 20 ~ 60%;
C) solution utilizing electrostatic textile technology to be obtained by b prepares complex fiber material on eptfe membrane, and complex fiber material is dry at room temperature in vacuo, removing residual solvent;
D) duplicature obtained is coated on nickel-titanium alloy framework surface.
For prednisolone, when the medicine overlay film frame length of Endovascular aortic repair is 105mm, diameter is 24mm, during pharmaceutical film thickness 10 μm, is reached for 4.4mg/mm by the prednisolone concentration that pharmaceutical film wraps up
3namely good curative effect can be had; When the medicine overlay film frame length of Endovascular aortic repair is 215mm, diameter is 46mm, during pharmaceutical film thickness 1 μm, is reached for 7mg/mm by the prednisolone concentration that pharmaceutical film wraps up
3namely good curative effect can be had.
Embodiment effect and effect
In the medicine overlay film frame implant into body of Endovascular aortic repair provided by the invention, not only can completely cut off breach, and the sustained release on medicine overlay film frame, reach and suppress pathological changes to occur, reduce inflammation reaction, thus reduce the object of the postoperative adverse events generation of inner cavity insulation.
Above embodiment be only the present invention conceive under basic explanation, do not limit the invention.And according to any equivalent transformation that technical scheme of the present invention is done, all belong to protection scope of the present invention.
Claims (6)
1. a medicine overlay film frame for Endovascular aortic repair, comprises the eptfe membrane on nickel-titanium alloy framework and its surface, it is characterized in that:
Wherein, also wrap up one deck pharmaceutical film outward at described eptfe membrane, described pharmaceutical film thickness is 1 ~ 10 μm.
2. the medicine overlay film frame of Endovascular aortic repair according to claim 1, is characterized in that:
Wherein, described nickel-titanium alloy framework is hollow cylindrical, and the length of described nickel-titanium alloy framework is 105 ~ 215mm, and the internal diameter after strutting is 24 ~ 46mm.
3. the medicine overlay film frame of Endovascular aortic repair according to claim 1, is characterized in that:
Wherein, described pharmaceutical film is made up of complex fiber material, the mixed solution that described complex fiber material is made up of organic polymer and drug molecule, adopt electrostatic textile technology to make, described drug molecule is the combination of any one or 2 ~ 4 kinds in glucocorticoid, aspirin, rapamycin, paclitaxel.
4. the medicine overlay film frame of Endovascular aortic repair according to claim 3, is characterized in that:
Wherein, described glucocorticoid is any one in prednisolone, betamethasone, dexamethasone, beclomethasone.
5. the medicine overlay film frame of Endovascular aortic repair according to claim 3, is characterized in that:
Wherein, described organic polymer is any one in polylactic acid, Poly(D,L-lactide-co-glycolide, polylactic-co-glycolic acid.
6. the medicine overlay film frame for Endovascular aortic repair according to claim 3, is characterized in that:
Wherein, described organic polymer molecular weight is 5 ~ 500,000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510388578.3A CN104984408A (en) | 2015-07-03 | 2015-07-03 | Medicine covered stent used for aorta endovascular graft exclusion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510388578.3A CN104984408A (en) | 2015-07-03 | 2015-07-03 | Medicine covered stent used for aorta endovascular graft exclusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104984408A true CN104984408A (en) | 2015-10-21 |
Family
ID=54296380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510388578.3A Pending CN104984408A (en) | 2015-07-03 | 2015-07-03 | Medicine covered stent used for aorta endovascular graft exclusion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104984408A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1568907A (en) * | 2004-05-11 | 2005-01-26 | 复旦大学附属中山医院 | Artificial endovascular stent and preparation method thereof |
| CN201798829U (en) * | 2010-08-24 | 2011-04-20 | 上海索康医用材料有限公司 | Intravascular stent |
| CN102120059A (en) * | 2011-03-11 | 2011-07-13 | 东南大学 | Medicinal stent-graft for preventing and treating intrauterine adhesion |
| WO2012103501A1 (en) * | 2011-01-28 | 2012-08-02 | Merit Medical Systems, Inc. | Electrospun ptfe coated stent and method of use |
| CN102973339A (en) * | 2011-09-05 | 2013-03-20 | 上海市第十人民医院 | Cardia stent with drug coating |
-
2015
- 2015-07-03 CN CN201510388578.3A patent/CN104984408A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1568907A (en) * | 2004-05-11 | 2005-01-26 | 复旦大学附属中山医院 | Artificial endovascular stent and preparation method thereof |
| CN201798829U (en) * | 2010-08-24 | 2011-04-20 | 上海索康医用材料有限公司 | Intravascular stent |
| WO2012103501A1 (en) * | 2011-01-28 | 2012-08-02 | Merit Medical Systems, Inc. | Electrospun ptfe coated stent and method of use |
| CN102120059A (en) * | 2011-03-11 | 2011-07-13 | 东南大学 | Medicinal stent-graft for preventing and treating intrauterine adhesion |
| CN102973339A (en) * | 2011-09-05 | 2013-03-20 | 上海市第十人民医院 | Cardia stent with drug coating |
Non-Patent Citations (1)
| Title |
|---|
| 冯家烜等: ""限制性裸支架预防腔内隔绝术后支架移植物远端再发夹层的研究"", 《中华普通外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xi et al. | In vitro and in vivo changes to PLGA/sirolimus coating on drug eluting stents | |
| Witt et al. | Short-term experience of porcine small intestinal submucosa patches in paediatric cardiovascular surgery | |
| EP3290008A1 (en) | Support and drug delivery device | |
| CN101454086A (en) | Polymer coatings containing drug powder of controlled morphology | |
| Boyle et al. | Solvent stimulated actuation of polyurethane-based shape memory polymer foams using dimethyl sulfoxide and ethanol | |
| US20090012595A1 (en) | Therapeutic Drug-Eluting Endoluminal Covering | |
| Lee et al. | Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery | |
| Lu et al. | Intelligent H2S release coating for regulating vascular remodeling | |
| WO2004112863A1 (en) | Biodegradable membrane-covered implant comprising chitosan | |
| CN104870028A (en) | Fully absorbable intraluminal devices and methods of manufacturing the same | |
| Lee et al. | Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stents | |
| US20130256928A1 (en) | Drug-Containing Bioabsorbable Fibers and Implants | |
| Lin et al. | Nerve growth factor released from a novel PLGA nerve conduit can improve axon growth | |
| Guo et al. | Biodegradable JDBM coating stent has potential to be used in the treatment of benign biliary strictures | |
| EP3563879A1 (en) | Absorbable iron-based instrument | |
| US9878073B2 (en) | Nitric oxide-eluting bioresorbable stents for percutaneous coronary interventions | |
| CN204890717U (en) | Medicine tectorial membrane support that isolated art of aorta intracavity was used | |
| JP2014501576A5 (en) | ||
| Andukuri et al. | Evaluation of the effect of expansion and shear stress on a self-assembled endothelium mimicking nanomatrix coating for drug eluting stents in vitro and in vivo | |
| CN104984408A (en) | Medicine covered stent used for aorta endovascular graft exclusion | |
| Arafat et al. | Pharmaceutical development of 5-fluorouracil-eluting stents for the potential treatment of gastrointestinal cancers and related obstructions | |
| Lee et al. | Promoting vascular healing using nanofibrous ticagrelor-eluting stents | |
| CN109966564B (en) | Drug-loaded balloon and preparation method thereof | |
| Dai et al. | A novel UV-curable extravascular stent to prevent restenosis of venous grafts | |
| CN101069660A (en) | Biliary-tract carriage carrying about medicine and preparing method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151021 |
|
| WD01 | Invention patent application deemed withdrawn after publication |